ASP Isotopes Restarts Silicon-28 Facility, Stock Up 12.3%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: seekingalpha
- Successful Facility Restart: ASP Isotopes has successfully restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, which has operated for over three weeks at target enrichment levels following nine months of engineering modifications, and expects to make initial commercial shipments in Q3, significantly enhancing its competitive position in the quantum computing and next-generation semiconductor markets.
- Commercial Contracts Signed: The company has signed three commercial contracts for enriched Silicon-28 with U.S.-based customers, reflecting the growing demand for quantum computing and advanced semiconductors, indicating that ASP Isotopes is strategically positioning itself in the critical materials market with potential for substantial revenue growth.
- Sample Shipment Progress: ASP Isotopes shipped its first samples of enriched Silicon-28 to a U.S. customer in August 2025, with independent analysis confirming that enrichment levels aligned with theoretical calculations, marking a significant milestone in both technical and market validation, thereby boosting customer confidence.
- Customer Feedback and Improvements: Following customer site visits in H2 2025, the company began implementing further modifications to the facility, which not only aids in enhancing production efficiency but also increases customer satisfaction, thereby driving future market expansion and sales growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASPI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASPI
Wall Street analysts forecast ASPI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.770
Low
11.00
Averages
12.00
High
13.00
Current: 7.770
Low
11.00
Averages
12.00
High
13.00
About ASPI
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASP Isotopes and Boot Barn See Active Options Trading
- ASP Isotopes Options Volume: ASP Isotopes Inc (ASPI) saw an options trading volume of 35,367 contracts today, representing approximately 3.5 million shares, which is about 86.9% of its average daily trading volume of 4.1 million shares over the past month, indicating strong market interest in its future performance.
- High Strike Call Activity: Within ASPI, the $7 strike call option has been particularly active, with 6,260 contracts traded today, representing approximately 626,000 underlying shares, suggesting increased investor expectations for the stock's upward movement.
- Boot Barn Options Activity: Boot Barn Holdings Inc (BOOT) recorded an options trading volume of 6,761 contracts today, equivalent to approximately 676,100 shares, or about 84.2% of its average daily trading volume of 802,935 shares over the past month, reflecting investor interest in its stock.
- Active Call Options: The $160 strike call option for BOOT saw a trading volume of 2,532 contracts today, representing approximately 253,200 underlying shares, indicating a positive sentiment regarding the company's future growth prospects.
See More
ASP Isotopes Restarts Silicon-28 Enrichment Facility in South Africa
- Facility Restart Success: ASP Isotopes has successfully restarted the first 18 stages of its Silicon-28 enrichment facility in South Africa, which has now operated for over three weeks at target enrichment levels, and expects to fulfill its supply agreements with U.S. customers in Q3, significantly enhancing its market competitiveness.
- Stock Price Surge: Following the announcement of the facility restart, ASP Isotopes' shares surged over 24% on Tuesday, marking its best single-day gain since October last year, reflecting strong investor confidence in the company's growth potential.
- Technical Optimizations Implemented: Over the past nine months, the company has made numerous modifications to non-core components of the facility, including valves, compressors, and piping, ensuring the efficient operation of core enrichment technology, thereby enhancing overall production safety and efficiency and improving customer satisfaction.
- Strong Market Demand: Silicon-28, being the most abundant and stable silicon isotope, accounts for 92.2% of naturally occurring silicon, and its demand in quantum computing and semiconductors is increasing, prompting ASP Isotopes to plan for expanded production capabilities in the coming quarters to meet the needs of these emerging technologies.
See More
ASP Isotopes Restarts Silicon-28 Facility, Stock Up 12.3%
- Successful Facility Restart: ASP Isotopes has successfully restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, which has operated for over three weeks at target enrichment levels following nine months of engineering modifications, and expects to make initial commercial shipments in Q3, significantly enhancing its competitive position in the quantum computing and next-generation semiconductor markets.
- Commercial Contracts Signed: The company has signed three commercial contracts for enriched Silicon-28 with U.S.-based customers, reflecting the growing demand for quantum computing and advanced semiconductors, indicating that ASP Isotopes is strategically positioning itself in the critical materials market with potential for substantial revenue growth.
- Sample Shipment Progress: ASP Isotopes shipped its first samples of enriched Silicon-28 to a U.S. customer in August 2025, with independent analysis confirming that enrichment levels aligned with theoretical calculations, marking a significant milestone in both technical and market validation, thereby boosting customer confidence.
- Customer Feedback and Improvements: Following customer site visits in H2 2025, the company began implementing further modifications to the facility, which not only aids in enhancing production efficiency but also increases customer satisfaction, thereby driving future market expansion and sales growth.
See More
ASP Isotopes Q1 Earnings Exceed Expectations
- Strong Financial Performance: ASP Isotopes reported Q1 revenue of $4.18 million, a remarkable 278% year-over-year increase, surpassing analyst expectations of $3.68 million, although it recorded a loss of $0.06 per share, better than the anticipated $0.28 loss, indicating robust revenue growth momentum.
- Radiopharmaceuticals Lead Revenue: The radiopharmaceutical segment accounted for approximately $3.4 million in revenue, while LNG operations linked to Renergen contributed about $600,000, showcasing the company's success in diversifying its revenue streams.
- Future Product Delivery Plans: The company expects to begin deliveries of enriched silicon-28 products around mid-2026, which are critical in semiconductor and quantum computing applications for reducing signal interference in advanced chips, thereby strengthening its market position.
- Expansion Plans and Market Outlook: ASP Isotopes plans to expand its radiopharmacy operations and advance several radiopharmaceutical products into early-phase clinical trials, targeting an annual EBITDA exceeding $300 million by 2031, reflecting its long-term growth potential.
See More
ASP Isotopes Signs MoU with European Company for HALEU Supply
- MoU Extended to 2030: ASP Isotopes' subsidiary Quantum Leap Energy has signed a memorandum of understanding (MoU) with a European nuclear technology company that extends through 2030, establishing a framework for the European partner to supply uranium feedstock to QLE, thereby laying the groundwork for future nuclear energy supply.
- Rising Demand for HALEU: With increasing demand for high assay low-enriched uranium (HALEU), particularly among advanced nuclear reactor developers, ASP Isotopes' shares rose nearly 5% in Monday's pre-market trading, reflecting strong market interest in securing non-Russian uranium supplies.
- Potential Delivery Timeline: The MoU outlines that potential uranium deliveries could begin in 2028 and scale up through 2036, depending on reactor development timelines and fuel demand, indicating the company's strategic foresight in aligning with future market needs.
- Diversified Business Strategy: ASP Isotopes is not only focused on nuclear energy but also shows potential in AI data centers and semiconductor chips, with retail sentiment around its stock remaining neutral, suggesting investor attention and expectations regarding its diversified strategic initiatives.
See More
ASP Isotopes Signs MOU with Quantum Leap Energy for HALEU Supply
- Strategic Partnership: ASP Isotopes has signed a non-binding MOU with Quantum Leap Energy to explore long-term collaboration with a European nuclear technology firm, aiming to address the growing global demand for high assay low enriched uranium (HALEU), which is expected to enhance the company's competitiveness in the nuclear energy market.
- Technical Assessment Plan: Under the MOU, both parties will conduct a technical and economic assessment to determine the feasibility of HALEU supply, covering operational requirements, production scalability, and commercial models, which are crucial for supporting future nuclear energy projects.
- Rising Market Demand: The global demand for HALEU is increasing, particularly from next-generation reactor developers, and the signing of this MOU signifies a significant step for QLE in meeting both domestic and international customer needs, potentially strengthening its market position.
- Timeline and Deliveries: The MOU is effective until December 31, 2030, with potential HALEU deliveries expected to begin in 2028 and scale up according to the partner's reactor development timeline, indicating QLE's strategic positioning within the nuclear fuel supply chain.
See More
ASP Isotopes and Boot Barn See Active Options Trading
- ASP Isotopes Options Volume: ASP Isotopes Inc (ASPI) saw an options trading volume of 35,367 contracts today, representing approximately 3.5 million shares, which is about 86.9% of its average daily trading volume of 4.1 million shares over the past month, indicating strong market interest in its future performance.
- High Strike Call Activity: Within ASPI, the $7 strike call option has been particularly active, with 6,260 contracts traded today, representing approximately 626,000 underlying shares, suggesting increased investor expectations for the stock's upward movement.
- Boot Barn Options Activity: Boot Barn Holdings Inc (BOOT) recorded an options trading volume of 6,761 contracts today, equivalent to approximately 676,100 shares, or about 84.2% of its average daily trading volume of 802,935 shares over the past month, reflecting investor interest in its stock.
- Active Call Options: The $160 strike call option for BOOT saw a trading volume of 2,532 contracts today, representing approximately 253,200 underlying shares, indicating a positive sentiment regarding the company's future growth prospects.
See More
ASP Isotopes Restarts Silicon-28 Enrichment Facility in South Africa
- Facility Restart Success: ASP Isotopes has successfully restarted the first 18 stages of its Silicon-28 enrichment facility in South Africa, which has now operated for over three weeks at target enrichment levels, and expects to fulfill its supply agreements with U.S. customers in Q3, significantly enhancing its market competitiveness.
- Stock Price Surge: Following the announcement of the facility restart, ASP Isotopes' shares surged over 24% on Tuesday, marking its best single-day gain since October last year, reflecting strong investor confidence in the company's growth potential.
- Technical Optimizations Implemented: Over the past nine months, the company has made numerous modifications to non-core components of the facility, including valves, compressors, and piping, ensuring the efficient operation of core enrichment technology, thereby enhancing overall production safety and efficiency and improving customer satisfaction.
- Strong Market Demand: Silicon-28, being the most abundant and stable silicon isotope, accounts for 92.2% of naturally occurring silicon, and its demand in quantum computing and semiconductors is increasing, prompting ASP Isotopes to plan for expanded production capabilities in the coming quarters to meet the needs of these emerging technologies.
See More
ASP Isotopes Restarts Silicon-28 Facility, Stock Up 12.3%
- Successful Facility Restart: ASP Isotopes has successfully restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, which has operated for over three weeks at target enrichment levels following nine months of engineering modifications, and expects to make initial commercial shipments in Q3, significantly enhancing its competitive position in the quantum computing and next-generation semiconductor markets.
- Commercial Contracts Signed: The company has signed three commercial contracts for enriched Silicon-28 with U.S.-based customers, reflecting the growing demand for quantum computing and advanced semiconductors, indicating that ASP Isotopes is strategically positioning itself in the critical materials market with potential for substantial revenue growth.
- Sample Shipment Progress: ASP Isotopes shipped its first samples of enriched Silicon-28 to a U.S. customer in August 2025, with independent analysis confirming that enrichment levels aligned with theoretical calculations, marking a significant milestone in both technical and market validation, thereby boosting customer confidence.
- Customer Feedback and Improvements: Following customer site visits in H2 2025, the company began implementing further modifications to the facility, which not only aids in enhancing production efficiency but also increases customer satisfaction, thereby driving future market expansion and sales growth.
See More
ASP Isotopes Q1 Earnings Exceed Expectations
- Strong Financial Performance: ASP Isotopes reported Q1 revenue of $4.18 million, a remarkable 278% year-over-year increase, surpassing analyst expectations of $3.68 million, although it recorded a loss of $0.06 per share, better than the anticipated $0.28 loss, indicating robust revenue growth momentum.
- Radiopharmaceuticals Lead Revenue: The radiopharmaceutical segment accounted for approximately $3.4 million in revenue, while LNG operations linked to Renergen contributed about $600,000, showcasing the company's success in diversifying its revenue streams.
- Future Product Delivery Plans: The company expects to begin deliveries of enriched silicon-28 products around mid-2026, which are critical in semiconductor and quantum computing applications for reducing signal interference in advanced chips, thereby strengthening its market position.
- Expansion Plans and Market Outlook: ASP Isotopes plans to expand its radiopharmacy operations and advance several radiopharmaceutical products into early-phase clinical trials, targeting an annual EBITDA exceeding $300 million by 2031, reflecting its long-term growth potential.
See More
ASP Isotopes Signs MoU with European Company for HALEU Supply
- MoU Extended to 2030: ASP Isotopes' subsidiary Quantum Leap Energy has signed a memorandum of understanding (MoU) with a European nuclear technology company that extends through 2030, establishing a framework for the European partner to supply uranium feedstock to QLE, thereby laying the groundwork for future nuclear energy supply.
- Rising Demand for HALEU: With increasing demand for high assay low-enriched uranium (HALEU), particularly among advanced nuclear reactor developers, ASP Isotopes' shares rose nearly 5% in Monday's pre-market trading, reflecting strong market interest in securing non-Russian uranium supplies.
- Potential Delivery Timeline: The MoU outlines that potential uranium deliveries could begin in 2028 and scale up through 2036, depending on reactor development timelines and fuel demand, indicating the company's strategic foresight in aligning with future market needs.
- Diversified Business Strategy: ASP Isotopes is not only focused on nuclear energy but also shows potential in AI data centers and semiconductor chips, with retail sentiment around its stock remaining neutral, suggesting investor attention and expectations regarding its diversified strategic initiatives.
See More
ASP Isotopes Signs MOU with Quantum Leap Energy for HALEU Supply
- Strategic Partnership: ASP Isotopes has signed a non-binding MOU with Quantum Leap Energy to explore long-term collaboration with a European nuclear technology firm, aiming to address the growing global demand for high assay low enriched uranium (HALEU), which is expected to enhance the company's competitiveness in the nuclear energy market.
- Technical Assessment Plan: Under the MOU, both parties will conduct a technical and economic assessment to determine the feasibility of HALEU supply, covering operational requirements, production scalability, and commercial models, which are crucial for supporting future nuclear energy projects.
- Rising Market Demand: The global demand for HALEU is increasing, particularly from next-generation reactor developers, and the signing of this MOU signifies a significant step for QLE in meeting both domestic and international customer needs, potentially strengthening its market position.
- Timeline and Deliveries: The MOU is effective until December 31, 2030, with potential HALEU deliveries expected to begin in 2028 and scale up according to the partner's reactor development timeline, indicating QLE's strategic positioning within the nuclear fuel supply chain.
See More
